| scholarly article | Q13442814 |
| P356 | DOI | 10.3390/BS8100089 |
| P8608 | Fatcat ID | release_humoltfk4jbzbkoxca7y2uspvi |
| P932 | PMC publication ID | 6210697 |
| P698 | PubMed publication ID | 30262766 |
| P50 | author | Per G. Farup | Q39738707 |
| Jørgen Valeur | Q42886929 | ||
| P2860 | cites work | The WHO-5 Well-Being Index: a systematic review of the literature | Q27026850 |
| Microbiota and SCFA in lean and overweight healthy subjects | Q29615812 | ||
| Functional bowel disorders | Q29620328 | ||
| Reduced dietary intake of carbohydrates by obese subjects results in decreased concentrations of butyrate and butyrate-producing bacteria in feces | Q34001633 | ||
| Human gut microbiota changes reveal the progression of glucose intolerance | Q34980773 | ||
| Correlation between the human fecal microbiota and depression. | Q35179996 | ||
| The abundance of fecal Faecalibacterium prausnitzii in relation to obesity and gender in Chinese adults. | Q51330666 | ||
| Differential metabolic effects of oral butyrate treatment in lean versus metabolic syndrome subjects. | Q55021279 | ||
| Gut microbiota, short chain fatty acids, and obesity across the epidemiologic transition: the METS-Microbiome study protocol | Q58798926 | ||
| The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress | Q60707901 | ||
| Review article: short chain fatty acids as potential therapeutic agents in human gastrointestinal and inflammatory disorders | Q63804759 | ||
| Pretreatment methods prior to gaschromatographic analysis of volatile fatty acids from faecal samples | Q67599259 | ||
| Short-chain fatty acids in the proximal gastrointestinal tract of healthy subjects | Q70418782 | ||
| Action and function of Faecalibacterium prausnitzii in health and disease | Q88135349 | ||
| Colonic butyrate- algesic or analgesic? | Q35328232 | ||
| Altered faecal and mucosal microbial composition in post-infectious irritable bowel syndrome patients correlates with mucosal lymphocyte phenotypes and psychological distress. | Q35529596 | ||
| Isovaleric acid in stool correlates with human depression | Q35566808 | ||
| Non-caloric artificial sweeteners and the microbiome: findings and challenges | Q35592115 | ||
| Deviations in human gut microbiota: a novel diagnostic test for determining dysbiosis in patients with IBS or IBD | Q35631365 | ||
| Proteobacteria: microbial signature of dysbiosis in gut microbiota | Q35713659 | ||
| Faecal short-chain fatty acids - a diagnostic biomarker for irritable bowel syndrome? | Q36001130 | ||
| Evidence for greater production of colonic short-chain fatty acids in overweight than lean humans. | Q37676116 | ||
| Influence of gut microbiota on neuropsychiatric disorders | Q38635869 | ||
| Alterations of gut microbiota in patients with irritable bowel syndrome: A systematic review and meta-analysis | Q38864862 | ||
| The neuropharmacology of butyrate: The bread and butter of the microbiota-gut-brain axis? | Q38877862 | ||
| Irritable bowel syndrome: a gut microbiota-related disorder? | Q39018403 | ||
| Role of the Gut Microbiome in the Pathogenesis of Obesity and Obesity-Related Metabolic Dysfunction | Q39133345 | ||
| Intestinal fermentation in patients with self-reported food hypersensitivity: painful, but protective? | Q41761911 | ||
| Role of the Gastrointestinal Tract Microbiome in the Pathophysiology of Diabetes Mellitus | Q42706747 | ||
| Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome | Q43244921 | ||
| Effect of exclusive enteral nutrition on gut microflora function in children with Crohn's disease | Q44474316 | ||
| Fatigue in the general population: a translation and test of the psychometric properties of the Norwegian version of the fatigue severity scale | Q45250666 | ||
| Dysbiotic Proteobacteria expansion: a microbial signature of epithelial dysfunction. | Q45957537 | ||
| The effects of butyrate enemas on visceral perception in healthy volunteers. | Q46002158 | ||
| Effects of Antidiabetic Drugs on Gut Microbiota Composition | Q46295791 | ||
| Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug | Q46362610 | ||
| Similar Fecal Microbiota Signatures in Patients With Diarrhea-Predominant Irritable Bowel Syndrome and Patients With Depression | Q46477060 | ||
| Dysbiosis Signatures of Gut Microbiota Along the Sequence from Healthy, Young Patients to Those with Overweight and Obesity | Q47252559 | ||
| Intestinal microbiome-gut-brain axis and irritable bowel syndrome. | Q47773748 | ||
| Butyrate reduces appetite and activates brown adipose tissue via the gut-brain neural circuit | Q47987772 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Switzerland | Q39 |
| feces | Q496 | ||
| obesity | Q12174 | ||
| P304 | page(s) | 89 | |
| P577 | publication date | 2018-09-27 | |
| P1433 | published in | Behavioral sciences (Basel, Switzerland) | Q27724027 |
| P1476 | title | Faecal Microbial Markers and Psychobiological Disorders in Subjects with Morbid Obesity. A Cross-Sectional Study | |
| P478 | volume | 8 |
Search more.